The US Food and Drugs Administration once proposed a regulation to ban the use of three antibiotics in cattle feed, where they act to promote growth, not to fight disease. The industry opposed the measure and won. That was 35 years ago. The practice is still being used today, even though the loss of efficient antibiotics and the return of infectious diseases is now a clear and present danger to the lives of millions.
Former editor-in-chief of Science magazine Donald Kennedy was involved in the FDA proposal back then and has recently revisited the issue in an editorial (Science (2013) 342, 777) . Around three quarters of antibiotics sold in the US are for veterinary use, says Kennedy. While inappropriate prescriptions for and inadequate use by human patients also contribute to the problem, Kennedy argues that "antibiotic resistance will be solved only when we end the use (or rather, the abuse) of these agents in veterinary medicine."
Kennedy now sees new hope, as a new FDA draft guideline, known as Guidance #213, could be implemented soon. It would be none too early, as a recent report from the US Centers for Disease Control and Prevention (CDC) describes the dramatic extent of the antibiotics crisis (Antibiotic Resistance Threats in the United States 2013, http://www.cdc.gov/drugresistance/ threat-report-2013/) and current research and development offers only very few and faint silver linings.
Antibiotics apocalypse
The report, aiming to provide crucial information on the dangers of spreading resistance traits to policy makers, medical professionals and patients alike, distinguishes three threat levelsnamely urgent, serious, and concerning. Between them, multidrug-resistant bacteria kill 23,000 people per year in the US, the report estimates. The latest figures for Europe, at 25,000 casualties, are very similar.
Among the urgent threats are carbapenem-resistant Enterobacteriaceae (CRE), a group of bacteria that have become resistant against "all or nearly all" of today's antibiotics, including carbapenems, which are typically reserved as an antibiotic of last resort. If infections enter the bloodstream, there is only a 50% survival rate. The two most common groups of CRE, Klebsiella and Escherichia coli, account for around 600 deaths in the US per year.
Another antibiotic-resistant pathogen is the gonorrhoea agent, Neisseria gonorrhoeae. While not normally fatal, gonorrhoea spreads easily and can cause severe complications in reproductive functions. In response to emerging resistance problems, the CDC has updated its treatment guidelines. It now recommends only ceftriaxone plus either azithromycin or doxycycline as first-line treatment for gonorrhoea.
Feature
The third and final 'urgent' threat is Clostridium difficile, a bacterium that commonly invades the intestines of patients whose own commensal bacteria have been weakened by treatment with antibiotics. As antibiotics are the root of the problem here, they cannot easily be used to fight C. difficile invasion -repeated application will increase the risk that the infection becomes intractable. As an experimental therapy, some doctors have started treating this problem by transferring gut microbiota (Curr. Biol. (2013) , 23, R359-R362).
C. difficile infection causes lifethreatening diarrhoea and is now responsible for 14,000 deaths a year in the US alone. The mortality has increased dramatically since the year 2000, when a new strain emerged that is resistant to antibiotics commonly used to treat other infections. However, in contrast to the other diseases discussed in the report, resistance to the drugs used against this pathogen is not a problem yet. Therefore, the CDC has not included the 14,000 deaths it Bacterial infections resistant to antibiotics kill 23,000 people per year in the US alone, a recent report warns. This crisis is man-made, as misuse of the miracle drugs over decades has thrown away their life-saving potential. Michael Gross reports.
Antibiotics in crisis
Critical mass: Bacteria with multiple drug resistance kill around 23,000 people per year in the US alone, and a similar number across Europe. That figure corresponds to the capacity of the Arthur Ashe Stadium in New York shown here, or the O2 Arena in London. (Photo: Wikimedia Commons/davidwboswell) causes in its estimate of 23,000 victims of antibiotics resistance.
The drug-resistant threats classed as serious include the much publicised 'hospital superbug' MRSA (methicillinresistant Staphylococcus aureus) along with resistant strains of Streptococcus, Salmonella, Enterobacteriaceae, and tuberculosis, among others. MRSA alone is responsible for almost half of the death toll, with 11,285 deaths per year in the US alone. However, the incidence of healthcare-associated MRSA infections seems to be declining, as preventive hygiene measures in hospitals are showing effect.
Another serious threat is Streptococcus pneumoniae, which causes 7,000 deaths per year in the US and is the main cause of bacterial pneumonia and meningitis there. Around 1,700 deaths per year are blamed on a group of Enterobacteriaceae that carry a broad spectrum beta-lactamase enzyme, which enables them to overcome all antibiotics of the penicillin and the cephalosporin groups.
Tuberculosis is listed as serious in the US, but is one of the most urgent resistance problems worldwide. The 2013 tuberculosis report of the WHO estimates that in 2012 170,000 people worldwide died of multidrug-resistant tuberculosis.
Apart from the return of infectious diseases that we had thought we put behind us, the weakening of our antibiotic defence also has a knockon effect on the safety of medical procedures with intrinsic infection risks, including major surgery, organ transplant, chemotherapy for cancer, and premature births, as Ramanan Laxminarayan and colleagues warn in a recent review of the global situation of antibiotics resistance (Lancet Infect. Dis. (2013) 13, 1057-1098).
Urgent measures
In its report, the CDC recommends four "core actions" that can help to stop antibiotic resistance, including: prevention of infection through hygiene, immunisation, and correct use of antibiotics; improved monitoring infectious diseases as a foundation for strategic disease prevention; improving antibiotic "stewardship" and stopping misuse in medicine and in agriculture; and research to develop new drugs and diagnostics.
On the stewardship issue, the report notes that: "Perhaps the single most important action needed to greatly slow down the development and spread of antibiotic-resistant infections is to change the way antibiotics are used. Up to half of antibiotic use in humans and much of antibiotic use in animals is unnecessary and inappropriate and makes everyone less safe."
The sheer number of antibiotics prescriptions to patients in the US gives an indication that there remains a lot of work to be done in this respect.
In quite a few states of the US, the average number of antibiotics courses prescribed per year exceeds the population size, so there is more than one treatment handed out per year per head. Intriguingly, the prescription habits seem to vary with latitude. Doctors in the states lining the West Coast prescribe the least antibiotics, while those in a strip running from the Great Lakes down to the Gulf Coast states are in the highest-prescribing category. Investigations into the underlying reasons are currently under way.
Perhaps the most worrying aspect of the excessive prescription of antibiotics is that it is committed by medical practitioners who should really know better by now. If even the doctors fail to handle antibiotics correctly, what hope is there that the patients do so?
Appealing to healthcare professionals to improve their stewardship, the report notes that there are tangible benefits for all sides -patients are more likely to be cured of their illnesses while suffering fewer side effects and healthcare providers can save costs by only administering the right drugs in the right dose. Moreover, good stewardship is necessary to preserve efficient antibiotics for future use, as there is an acute shortage of new drugs becoming available.
Part of the problem with the spread of antibiotics resistance is that the discovery of new types of antibiotics has dried up in the last decades. Twenty new classes of antibiotics were discovered before 1980, but only two since then. The report offers neither explanations nor solutions to this fundamental pipeline problem, but a few potential alternatives to antibiotics are already being investigated.
Silver linings
One promising way of making more of the limited number of antibiotics available is to use them in combinations and sequences designed to kill off bacteria more efficiently and to avoid resistance, rather than just picking a different drug at random if the first didn't work. Lejla Imamovic and Morten Sommer from the Technical University of Denmark have developed what they call "collateral sensitivity networks" for bacterial pathogens. The phenomenon of collateral sensitivity is simply based on the observation that specific adaptations making a bacterial strain resistant to one type of antibiotic Serious threat: Extended spectrum beta-lactamase-producing strains of Enterobacteriaceae, including Klebsiella species and E. coli, are responsible for around 1,700 deaths per year in the US. (Photo: courtesy of CDC http://www.cdc.gov) come at a fitness cost and may make it more sensitive to another.
Working with E. coli, for instance, Imamovic and Sommer could show that cycling of the drugs gentamicin and cefuroxime led to efficient eradication of the bacteria, including those that were resistant to one of the drugs. While this report is only a proof of principle, the authors anticipate that rationally designed deployment of already approved drugs in combination could improve the treatment of a number of diseases where evolved resistance is a problem.
Two other emerging approaches target the ability of bacteria to establish colonies in their host, and to persist in an inactive state. In a recent perspective article, Kaelyn Wilke and Erin Carlson from Indiana University in Bloomington, US, surveyed research targeting the bacterial histidine kinases, which are important signalling stations in the communications between bacteria invading a host (Sci. Trans. Med. (2013) 5, 203ps12) .
While this approach has already been tried in the 1990s, the authors argue that the compounds tried then were unsuitable for bacterial targets. Moreover, as pathogenic bacteria tend to rely on this kind of signalling for multiple functions crucial for their success in establishing an infection, successful histidine kinase inhibitors could disrupt so many functions at once that there would be no escape route for the pathogens.
Another problem affecting the success of existing antibiotics is the ability of some bacterial species to generate 'persister' populations consisting of a stochastically selected, genetically identical subpopulation that goes into an inactive state and is thus resilient to all drug treatments that target cell division or metabolism.
Recently, the group of Kim Lewis at Northeastern University in Boston, US, could demonstrate that a group of substances known as acyldepsipeptides can exterminate such persister cells (Nature (2013) 503, 365-370). These molecules enter the cell and wedge open the entrance to a protease named ClpP. Like the proteasome, this protease adopts a barrel shape with the active centre on the inside. Strict regulation of access to the cavity stops it from degrading proteins indiscriminately. By opening access to this reaction chamber, acyldepsipeptides promote large-scale proteolysis in the dormant cell, making it impossible for the persister to come back to life. While this approach is no cure for the problem of antibiotic resistance, it bears the promise of overcoming pathogen resilience in some types of chronic and relapsing infections.
One final remedy for bacterial infections that could conceivably provide a way out of the crisis surrounding antibiotics resistance is popular in the former Soviet republic of Georgia and in Poland, but virtually unknown in the rest of the world, to the extent that it isn't even mentioned in the CDC report. This method is phage therapy, i.e. the use of bacteriophages to kill pathogenic bacteria (see Curr. Biol. (2011) 21, R267-R270) .
Pioneered in 1919 by one of the discoverers of bacteriophages, the French-Canadian microbiologist Felix d'Herelle, phage therapy fell into oblivion when antibiotics conquered the world. Now that antibiotics are in crisis due to their widespread misuse, phage therapy is experiencing a modest revival, expanding from its spiritual home in Tbilisi, Georgia.
In Germany, for instance, Christine Rohde at the Leibniz Institute DSMZ (German Collection of Microrganisms and Cell Cultures) at Braunschweig looks after a collection already comprising over 350 strains of phages. The institute currently calls for university students to help as 'phage trappers' to extend their collection, with a view to use phages in medical research.
The DSMZ has already collaborated with the phage institute in Tbilisi to develop phage cocktails against MRSA. Currently, the institute works on the characterisation of phages to fight bacteria of the order Burkholderiales, which play a role in the biofilms in the lungs of patients with COPD (chronically obstructive pulmonary disease) or cystic fibrosis. The institute also handles genomics and bioinformatics for the species collected, while the Helmholtz Centre for Infection Research nearby provides examination of phage morphology.
Meanwhile, in France, Laurent Debarbieux and colleagues at the Pasteur Institute in Paris, where Felix d'Herelle discovered phages and conducted the first experiments for therapies, are also revisiting the medical potential of phages. Specifically, Debarbieux's group is studying model systems of acute lung infections and of intestinal colonies.
As phages are highly specialised to infect bacterial cells, it is extremely unlikely they could harm human cells when applied as therapy, and indeed no adverse side effects have been reported in Eastern Europe where phage cocktails have been applied for many decades.
Problems standing in the way of formal recognition for phage therapy in western countries are more of a bureaucratic nature -phages are difficult to categorise, as they are neither molecules nor living beings as such, and hard to standardise, as they aren't produced synthetically.
With all these modest silver linings, it appears at least conceivable that the antibiotic apocalypse, i.e. the complete loss of the advantage that antibiotics have brought us in the second half of the 20 th century, can still be averted. It would help, however, if authorities could finally stop the blatant misuse of antibiotics in agriculture and medicine.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk
Massive misuse: The majority of antibiotics sold in the US are used in agriculture, where they are typically used to promote growth rather than to fight dangerous diseases. Although this practice was identified as a contributor to antibiotics resistance decades ago, it has continued to this day. (Photo: Nerys H. Gross.)
